GSK, Teva on-again, off-again lawsuit is back on: Will 'skinny labeling' get a reprieve?

Just when it seemed generic drug company carve-outs—aka “skinny labels”—might be in permanent peril, a federal appeals court is giving Teva another chance to prove its case.

GlaxoSmithKline won an appeals panel ruling against Teva in the fall—and the $235 million judgment that went with it. But Teva and eight other generic drug makers filed amicus briefs asking for the full Federal Circuit Court to review the decision. Wednesday, they said yes.